CDK4 and neoplasm: The addition of the PI3Kα inhibitor alpelisib to fulvestrant has demonstrated efficacy in CDK4/6 inhibitor naïve PI3Kα mutant tumours, with a very limited number of patients receiving prior CDK4/6 treatment included in the SOLAR-1 Phase III trial19.